|
1
|
Marmot MG, Altman DG, Cameron DA, Dewar
JA, Thompson SG and Wilcox M: The benefits and harms of breast
cancer screening: An independent review. Br J Cancer.
108:2205–2240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kaufmann M, von Minckwitz G, Mamounas EP,
Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant
M, Harris JR, et al: Recommendations from an international
consensus conference on the current status and future of
neoadjuvant systemic therapy in primary breast cancer. Ann Surg
Oncol. 19:1508–1516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bear HD, Anderson S, Smith RE, Geyer CE
Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R,
Kahlenberg MS, et al: Sequential preoperative or postoperative
docetaxel added to preoperative doxorubicin plus cyclophosphamide
for operable breast cancer: National Surgical Adjuvant Breast and
Bowel Project Protocol B-27. J Clin Oncol. 24:2019–2027. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
EBCTCG (Early Breast Cancer Trialists'
Collaborative Group). McGale P, Taylor C, Correa C, Cutter D, Duane
F, Ewertz M, Gray R, Mannu G, Peto R, et al: Effect of radiotherapy
after mastectomy and axillary surgery on 10-year recurrence and
20-year breast cancer mortality: Meta-analysis of individual
patient data for 8135 women in 22 randomised trials. Lancet.
383:2127–2135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Charafe-Jauffret E, Ginestier C and
Birnbaum D: Breast cancer stem cells: Tools and models to rely on.
BMC Cancer. 9:2022009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Glinsky GV: Stem cell origin of
death-from-cancer phenotypes of human prostate and breast cancers.
Stem Cell Rev. 3:79–93. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krivtsov AV, Twomey D, Feng Z, Stubbs MC,
Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, et al:
Transformation from committed progenitor to leukaemia stem cell
initiated by MLL-AF9. Nature. 442:818–822. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao RC, Zhu YS and Shi Y: New hope for
cancer treatment: Exploring the distinction between normal adult
stem cells and cancer stem cells. Pharmacol Ther. 119:74–82. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stingl J, Eirew P, Ricketson I, Shackleton
M, Vaillant F, Choi D, Li HI and Eaves CJ: Purification and unique
properties of mammary epithelial stem cells. Nature. 439:993–997.
2006.PubMed/NCBI
|
|
11
|
O'Brien CA, Kreso A and Jamieson CH:
Cancer stem cells and self-renewal. Clin Cancer Res. 16:3113–3120.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen H, Yan Y, Davidson TL, Shinkai Y and
Costa M: Hypoxic stress induces dimethylated histone H3 lysine 9
through histone methyltransferase G9a in mammalian cells. Cancer
Res. 66:9009–9016. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chaudary N and Hill RP: Hypoxia and
metastasis in breast cancer. Breast Dis. 26:55–64. 2006.PubMed/NCBI
|
|
17
|
Nuyten DS, Hastie T, Chi JT, Chang HY and
van de Vijver MJ: Combining biological gene expression signatures
in predicting outcome in breast cancer: An alternative to
supervised classification. Eur J Cancer. 44:2319–2329. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Samanta D, Gilkes DM, Chaturvedi P, Xiang
L and Semenza GL: Hypoxia-inducible factors are required for
chemotherapy resistance of breast cancer stem cells. Proc Natl Acad
Sci USA. 111:E5429–E5438. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Acconcia F and Marino M: The effects of
17beta-estradiol in cancer are mediated by estrogen receptor
signaling at the plasma membrane. Front Physiol. 2:302011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng S, Huang J, Zhou K, Zhang C, Xiang
Q, Tan Z, Wang T and Fu X: 17β-Estradiol enhances breast cancer
cell motility and invasion via extra-nuclear activation of
actin-binding protein ezrin. PLoS One. 6:e224392011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li L, Ren C, Yang G, Goltsov AA, Tabata K
and Thompson TC: Caveolin-1 promotes autoregulatory, Akt-mediated
induction of cancer-promoting growth factors in prostate cancer
cells. Mol Cancer Res. 7:1781–1791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kasagi S and Chen W: TGF-beta1 on
osteoimmunology and the bone component cells. Cell Biosci. 3:42013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prud'homme GJ: Pathobiology of
transforming growth factor beta in cancer, fibrosis and immunologic
disease, and therapeutic considerations. Lab Invest. 87:1077–1091.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akhurst RJ and Derynck R: TGF-beta
signaling in cancer - a double-edged sword. Trends Cell Biol.
11(Suppl 1): S44–S51. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lv ZD, Kong B, Li JG, Qu HL, Wang XG, Cao
WH, Liu XY, Wang Y, Yang ZC, Xu HM, et al: Transforming growth
factor-β 1 enhances the invasiveness of breast cancer cells by
inducing a Smad2-dependent epithelial-to-mesenchymal transition.
Oncol Rep. 29:219–225. 2013.PubMed/NCBI
|
|
27
|
Kong D, Li Y, Wang Z and Sarkar FH: Cancer
stem cells and epithelial-to-mesenchymal transition
(EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel).
3:716–729. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Santisteban M, Reiman JM, Asiedu MK,
Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC,
Manjili MH, et al: Immune-induced epithelial to mesenchymal
transition in vivo generates breast cancer stem cells.
Cancer Res. 69:2887–2895. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Soltanian S and Matin MM: Cancer stem
cells and cancer therapy. Tumour Biol. 32:425–440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang C, Ang BT and Pervaiz S: Cancer stem
cell: Target for anti-cancer therapy. FASEB J. 21:3777–3785. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang S, Cui B, Lai H, Liu G, Ghia EM,
Widhopf GF II, Zhang Z, Wu CC, Chen L, Wu R, et al: Ovarian cancer
stem cells express ROR1, which can be targeted for
anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA.
111:17266–17271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sakariassen PØ, Immervoll H and Chekenya
M: Cancer stem cells as mediators of treatment resistance in brain
tumors: Status and controversies. Neoplasia. 9:882–892. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rycaj K and Tang DG: Cancer stem cells and
radioresistance. Int J Radiat Biol. 90:615–621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pattarozzi A, Gatti M, Barbieri F, Würth
R, Porcile C, Lunardi G, Ratto A, Favoni R, Bajetto A, Ferrari A,
et al: 17beta-estradiol promotes breast cancer cell
proliferation-inducing stromal cell-derived factor-1-mediated
epidermal growth factor receptor transactivation: Reversal by
gefitinib pretreatment. Mol Pharmacol. 73:191–202. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu YF, Wu Q, Xu XM, Ren Y, Yu LN, Quan CS
and Li YL: Effects of 17β-estradiol on proliferation and migration
of MCF-7 cell by regulating expression of claudin-6. Zhonghua Bing
Li Xue Za Zhi. 39:44–47. 2010.(In Chinese). PubMed/NCBI
|
|
38
|
Fillmore CM, Gupta PB, Rudnick JA,
Caballero S, Keller PJ, Lander ES and Kuperwasser C: Estrogen
expands breast cancer stem-like cells through paracrine FGF/Tbx3
signaling. Proc Natl Acad Sci USA. 107:21737–21742. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Negulescu O, Bognar I, Lei J, Devarajan P,
Silbiger S and Neugarten J: Estradiol reverses TGF-beta1-induced
mesangial cell apoptosis by a casein kinase 2-dependent mechanism.
Kidney Int. 62:1989–1998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Silbiger S, Lei J, Ziyadeh FN and
Neugarten J: Estradiol reverses TGF-beta1-stimulated type IV
collagen gene transcription in murine mesangial cells. Am J
Physiol. 274:F1113–F1118. 1998.PubMed/NCBI
|
|
41
|
Kimura H, Braun RD, Ong ET, Hsu R, Secomb
TW, Papahadjopoulos D, Hong K and Dewhirst MW: Fluctuations in red
cell flux in tumor microvessels can lead to transient hypoxia and
reoxygenation in tumor parenchyma. Cancer Res. 56:5522–5528.
1996.PubMed/NCBI
|
|
42
|
Gillies RJ and Gatenby RA: Hypoxia and
adaptive landscapes in the evolution of carcinogenesis. Cancer
Metastasis Rev. 26:311–317. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Z and Rich JN: Hypoxia and hypoxia
inducible factors in cancer stem cell maintenance. Curr Top
Microbiol Immunol. 345:21–30. 2010.PubMed/NCBI
|
|
44
|
Liu J and Wang Z: Increased oxidative
stress as a selective anticancer therapy. Oxid Med Cell Longev.
2015:2943032015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liang D, Ma Y, Liu J, Trope CG, Holm R,
Nesland JM and Suo Z: The hypoxic microenvironment upgrades
stem-like properties of ovarian cancer cells. BMC Cancer.
12:2012012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Heddleston JM, Li Z, McLendon RE,
Hjelmeland AB and Rich JN: The hypoxic microenvironment maintains
glioblastoma stem cells and promotes reprogramming towards a cancer
stem cell phenotype. Cell Cycle. 8:3274–3284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
48
|
Cardoso F, Fallowfield L, Costa A,
Castiglione M and Senkus E: ESMO Guidelines Working Group: Locally
recurrent or metastatic breast cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
22(Suppl 6): vi25–vi30. 2011.PubMed/NCBI
|
|
49
|
An Y and Ongkeko WM: ABCG2: The key to
chemoresistance in cancer stem cells? Expert Opin Drug Metab
Toxicol. 5:1529–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Velasco-Velázquez MA, Yu Z, Jiao X and
Pestell RG: Cancer stem cells and the cell cycle: Targeting the
drive behind breast cancer. Expert Rev Anticancer Ther. 9:275–279.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ravandi F and Estrov Z: Eradication of
leukemia stem cells as a new goal of therapy in leukemia. Clin
Cancer Res. 12:340–344. 2006. View Article : Google Scholar : PubMed/NCBI
|
